Aprea logo 445pt.png
Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
November 06, 2019 09:15 ET | Aprea Therapeutics
BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 07, 2019 16:15 ET | Aprea Therapeutics
BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Announces Pricing of Initial Public Offering
October 02, 2019 23:03 ET | Aprea Therapeutics
BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor...